伊达比星在初治急性淋巴细胞白血病高危组患儿联合化疗中的使用和疗效观察

目的：观察长春新碱（VCR）和左旋门冬酰胺酶（L-asp）联合伊达比星（IDA）的VILD方案在治疗初治急性淋巴细胞白血病高危组患儿（HR-ALL）的效果。方法：回顾分析2005年2月-2013年4月在本院接受化疗的初治急性淋巴细胞白血病高危组患儿,33例使用VILD方案强化化疗,15例使用长春新碱和左旋门冬酰胺酶联合表柔比星（Epi）的VDLD方案强化化疗,比较两组的无事件生存期（EFS）和5年无事件生存率。结果：VILD方案治疗组和VDLD方案治疗组的EFS分别为（80.98±5.36）个月和（52.06±9.10）个月,5年无事件生存率为（83.3±7.0）%和（52.5±13.1）%（P=0.029）。结论：VILD方案治疗急性淋巴细胞白血病高危组患儿疗效优于VDLD方案。

Efficacy of a New Combination of Idarubicin,Vincristin and L-asp in Treatment of Previously Untreated High Risk Acute Lymphoblastic Leukemia

Objective：To evaluate the efficacy of VILD as an induction or intensive period chemotherapy for the treatment of previously untreated HR-ALL patients. Method：Retrospectively analyzed the previous untreated HR ALL patients treated with VILD or VDLD regimen,compare the EFS and 5-year survival rate. Result：Patients received VILD regimen during the intensive treatment period had a longer EFS of（80.98±5.36 ）months and a better 5-year survival rate of（83.3±7.0）% in comparison of that of the patients treated with VDLD,which were（52.06±9.10）months and（52.5±13.1）% （ P =0.029）.Conclusion：VILD used as intensive period treatment instead of VDLD had superior efficacy in treating previously untreated HR-ALL cases.